Results: 3 cases were diagnosed as EGPA and 1 was EGPA combined with allergic bronchopulmonary aspergillosis (ABPA). The age of onset was 28 to 59 years, with the average age of 44 years, and the course of disease was ranged from 1 month to 3 years. ANCA was negative of all those 4 patients. Airway hyperresponsiveness (AHR) of these patients varied from cough variant asthma (CVA) to refractory asthma. Patients were confirmed with chronic sinusitis by computer tomography (CT) scan, whereas clinical symptoms were nearly absent. Gastrointestinal, skin and neurological system were involved as extra-pulmonary manifestations. Eosinophilia of peripheral blood and induced sputum, pulmonary infiltration and peripheral neuropathy were found in 3 patients. 3 cases with elevated serum total IgE before using systemic glucosteroid. Eosinophilic infiltration in extravascular and intravascular space was verified by tissue biopsy in 3 cases with chronic inflammation in 1 case.
Conclusion:
EGPA patients who first suffered from respiratory symptoms are tend to have the negative result of ANCA. The degree of AHR is associated with the course of the disease. Patients with asthma complicated with eosinophilia and sinusitis should be aware of ruling out of EGPA. Background and Aims: Asthma and chronic obstructive pulmonary disease (COPD) are chronic airway inflammatory diseases. Although some differences exist in terms of aetiologies, clinical features, and treatment policies, these two diseases still share some common features.
Bronchial epithelial cells play important roles in the pathogenesis of both asthma and COPD. MicroRNAs are important regulators of gene expression. The aim of this study is to investigate the common microRNA changes in bronchial epithelial cells of asthma and COPD.
Methods: Primary bronchial epithelial cells from asthma (aHBE) and COPD (cHBE) patients and healthy subjects (nHBE) were cultured, and the RNAs were extracted for small RNA sequencing using next generation sequencing (NGS). The miRNA expression levels in aHBE and cHBE were compared to nHBE. We took a 2-fold change in the expression level as a significant change (up-regulation or down-regulation).
Results: Using NGS, we identified 28 up-regulated miRNAs and 17 down-regulated miRNAs in aHBE and 45 up-regulated miRNAs and 38 down-regulated miRNAs in cHBE. The common up-regulated miRNAs in both aHBE and cHBE were hsa-miR-10a-3p, hsa-miR-10a-5p, hsamiR-146a-5p, hsa-miR-203a, hsa-miR-3130-5p, hsa-miR-365a-5p, and hsa-miR-548d-5p, while hsa-miR-487a and hsa-miR-873-5p were downregulated in both aHBE and cHBE.
Conclusion: These common microRNA changes might play important roles in the pathogenesis of asthma and COPD. Further study is warranted to understand their targets and regulatory mechanisms, which might provide scientific basis for further treatment development. Background and Aims: Sphingosine 1 phosphate (S1P) regulates diverse biological responses. The aim of this study is to reveal the relationship between S1P and S1P receptors (S1PR) using human bronchial epithelial cells (BECs) and asthma model.
Methods:
Transcriptome analysis was performed for total RNA from BEAS-2B and Calu-3 cells stimulated with S1P, and asthma-related genes expression were identified. CCL 20 expression was evaluated using SiRNAs for S1PR knockdown. The effect of anti-CCL20 antibody and VPC23019, S1PR1/3 antagonist on eosinophilic airway inflammation, was examined in the ovalbumin (OVA)-induced murine asthma model.
Results: S1P upregulated asthma-related genes, including ADRB2, PTGER4, and CCL20 in BECs. The knockdown of S1PR3 reduced CCL20 expression. In the asthma model, anti-CCL20 antibody and VPC23019 significantly reduced the number of eosinophils in bronchoalveolar lavage fluid.
Conclusion: S1P/S1PR3 is shown to induce CCL20 expression and eosinophilic airway inflammation, suggesting their potential roles in asthma pathogenesis. 
